Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Profound thrombocytopenia after primary exposure to eptifibatide.

Norgard NB, Badgley BT.

Drug Healthc Patient Saf. 2010;2:163-7. doi: 10.2147/DHPS.S13239. Epub 2010 Sep 21.

PMID:
21701628
[PubMed]
Free PMC Article
2.

Acute profound thrombocytopenia associated with readministration of eptifibatide: case report and review of the literature.

Russell KN, Schnabel JG, Rochetto RP, Tanner MC.

Pharmacotherapy. 2009 Jul;29(7):867-74. doi: 10.1592/phco.29.7.867.

PMID:
19558261
[PubMed - indexed for MEDLINE]
3.

Eptifibatide-induced acute profound thrombocytopenia: a case report.

Graidis C, Golias C, Dimitriadis D, Dimitriadis G, Bitsis T, Dimitrelos I, Tsiakou A, Charalabopoulos K.

BMC Res Notes. 2014 Feb 25;7:107. doi: 10.1186/1756-0500-7-107.

PMID:
24564943
[PubMed - in process]
Free PMC Article
4.

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.

Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R.

J Invasive Cardiol. 2003 Jun;15(6):319-23.

PMID:
12777670
[PubMed - indexed for MEDLINE]
5.

Eptifibatide-associated acute, profound thrombocytopenia.

Coons JC, Barcelona RA, Freedy T, Hagerty MF.

Ann Pharmacother. 2005 Feb;39(2):368-72. Epub 2005 Jan 11. Review.

PMID:
15644467
[PubMed - indexed for MEDLINE]
6.

Reversible thrombocytopenia associated with eptifibatide.

Yoder M, Edwards RF.

Ann Pharmacother. 2002 Apr;36(4):628-30.

PMID:
11918511
[PubMed - indexed for MEDLINE]
7.

Eptifibatide-induced thrombocytopenia.

Refaat M, Smith AJ, Edmundowicz D.

J Thromb Thrombolysis. 2008 Apr;25(2):204-6. Epub 2007 Nov 16.

PMID:
18008040
[PubMed - indexed for MEDLINE]
8.

Acute profound thrombocytopenia associated with eptifibatide therapy.

Nagge J, Jackevicius C, Dzavik V, Ross JR, Seidelin P.

Pharmacotherapy. 2003 Mar;23(3):374-9.

PMID:
12627937
[PubMed - indexed for MEDLINE]
9.

Acute thrombocytopenia associated with eptifibatide therapy.

Khaykin Y, Paradiso-Hardy FL, Madan M.

Can J Cardiol. 2003 Jun;19(7):797-801.

PMID:
12813613
[PubMed - indexed for MEDLINE]
10.

Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.

Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM.

Circulation. 2010 Feb 16;121(6):784-91. doi: 10.1161/CIRCULATIONAHA.109.882746. Epub 2010 Feb 1.

PMID:
20124127
[PubMed - indexed for MEDLINE]
Free Article
11.

Eptifibatide-induced thrombocytopenia and thrombosis.

Epelman S, Nair D, Downey R, Militello M, Askari AT.

J Thromb Thrombolysis. 2006 Oct;22(2):151-4.

PMID:
17008982
[PubMed - indexed for MEDLINE]
12.

Profound thrombocytopenia associated with tirofiban: case report and review of literature.

Patel S, Patel M, Din I, Reddy CV, Kassotis J.

Angiology. 2005 May-Jun;56(3):351-5. Review.

PMID:
15889207
[PubMed - indexed for MEDLINE]
13.

Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.

Granada JF, Kleiman NS.

Am J Cardiovasc Drugs. 2004;4(1):31-41. Review.

PMID:
14967064
[PubMed - indexed for MEDLINE]
14.
15.

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

Goa KL, Noble S.

Drugs. 1999 Mar;57(3):439-62. Review.

PMID:
10193692
[PubMed - indexed for MEDLINE]
17.

[Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].

Agnelli D, Ottani F.

G Ital Cardiol (Rome). 2008 Feb;9(2):137-43. Italian.

PMID:
18383777
[PubMed - indexed for MEDLINE]
18.

Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.

Dyke CM, Bhatia D, Lorenz TJ, Marso SP, Tardiff BE, Hogeboom C, Harrington RA.

Ann Thorac Surg. 2000 Sep;70(3):866-71; discussion 871-2.

PMID:
11016325
[PubMed - indexed for MEDLINE]
19.

Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.

Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.

Circulation. 2002 Sep 17;106(12):1470-6.

PMID:
12234950
[PubMed - indexed for MEDLINE]
Free Article
20.

Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.

Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, Pepine CJ, Kopecky SL, Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ.

Circulation. 2000 Sep 5;102(10):1093-100.

PMID:
10973836
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk